To provide expert insights into the clinical relevance, innovation, and future potential of the FDA-registered randomised controlled trial exploring peripheral blood-derived regenerative cell injections after arthroscopic subchondral drilling for large knee cartilage defects.
Chahla and Gursoy affirm the value of this biologically driven treatment as a credible and scalable option for joint preservation. While further long-term data are necessary, this study lays the groundwork for transforming how large chondral defects are managed, particularly in younger or active patients not suited for joint replacement.
